Tauopathies are a set of neurodegenerative diseases identifiable by the aggregation of insoluble intracellular deposits of the microtubule associated protein tau. Among others, this class of diseases includes frontotemporal dementia (FTD), Pick’s disease, and supranuclear palsy. Though the precise pathology of tauopathies is poorly understood, most forms are associated with hyperphosphorylated tau and impaired clearance of tau through the ubiquitin-proteasome and autophagosome pathways. We attempt to explore the degradative properties of one specific tau variant, a serine to threonine missense mutation (S356T), which is strongly associated with an early onset behavioral variant frontotemporal dementia (bvFTD). Posttranslational modification at the S356 residue in tau controls its proteasomal degradation. Therefore, we hypothesize that the S356T variant exhibits impaired tau clearance compared to wildtype tau. To test this hypothesis, we use the pharmacological inhibitor Cycloheximide that prevents protein synthesis in both human embryonic epithelial cells (HEK293) and neurons transfected with wildtype and S356T tau protein. Cycloheximide has been shown to inhibit translation by binding to the E-site of the 60S ribosomal subunit and preventing protein elongation. This drug allows us to measure protein degradation without being confounded with new protein synthesis. We expect the amount of tau, relative to total protein, to be elevated in the S356T transfected cells after application of cycloheximide. If our hypothesis is correct, we plan to explore possible mechanisms behind the aberrant degradative properties of the S356T tau variant. By exploring the mechanisms through which tau mutants contribute to neuropathology, we hope to provide molecular insight into tau proteostasis that if successful could offer a promising therapeutic target.